Vivesto AB (STO:VIVE)

Market Cap	100.75M -19.3%
Revenue (ttm)	n/a
Net Income	-34.08M
EPS	-6.33
Shares Out	11.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,918
Open	9.29
Previous Close	9.10
Day's Range	9.11 - 9.80
52-Week Range	7.00 - 31.90
Beta	0.91
Analysts	n/a
Price Target	24.00 (+152.63%)
Earnings Date	Aug 6, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIVE

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 16, 2026

Data Sources Report a data error